Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
Saved in:
| Title: | Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy. |
|---|---|
| Authors: | Itzler R; CSL Behring, King of Prussia, Pennsylvania, USA., Buckner TW; Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, USA., Leebeek FWG; Department of Hematology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Miller J; Everest Clinical Research, New Jersey, USA., Recht M; National Bleeding Disorders Foundation, New York, New York, USA.; Yale University School of Medicine, New Haven, Connecticut, USA., Drelich D; CSL Behring, King of Prussia, Pennsylvania, USA., Monahan PE; CSL Behring, King of Prussia, Pennsylvania, USA., Pipe SW; Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA. |
| Source: | Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2024 May; Vol. 30 (3), pp. 709-719. Date of Electronic Publication: 2024 Mar 10. |
| Publication Type: | Journal Article; Clinical Trial, Phase III |
| Journal Info: | Publisher: Blackwell Science Country of Publication: England NLM ID: 9442916 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2516 (Electronic) Linking ISSN: 13518216 NLM ISO Abbreviation: Haemophilia Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2516 |
|---|---|
| DOI: | 10.1111/hae.14977 |
